Is ACADIA Pharmaceuticals (ACAD) Still Trading At A Discount As DAYBU Wins EU Approval?
ACADIA Pharmaceuticals (ACAD) is in focus after the European Commission granted marketing authorization for DAYBU, trofinetide, as the first approved Rett syndrome treatment in the European Union and associated European Economic Area countries.
Despite the DAYBU approval, ACADIA Pharmaceuticals’ share price slipped 3.24% over the last trading day and 2.09% over the past week, although a 36.75% 90 day share price return and 67.21% five year total shareholder return indicate momentum that has been building over time.
Scan other rare disease opportunities using the hand picked 18 high quality undiscovered gems that share ACADIA Pharmaceuticals’ focus on specialized treatments and potentially under the radar growth stories.
The market reaction to ACADIA Pharmaceuticals’ DAYBU milestone has split opinion. Bulls see a rare disease platform gaining traction. Bears point to recent share price softness. The valuation numbers now show which side the evidence supports.
Most Popular Narrative: 11% Undervalued
ACADIA Pharmaceuticals closed at $29.58 against a most followed fair value narrative of $33.25 per share, which frames the recent DAYBU news against a higher long term earnings story.
ACADIA's pipeline momentum, with 9 disclosed programs and multiple late-stage clinical readouts expected by 2027, positions the company to significantly diversify its revenue streams, reducing risk from single-product dependence and providing potential for margin expansion as new products are launched.
Want to see what sits behind that pipeline claim. Revenue is projected on a firm path, margins are expected to reset, and the future profit multiple does a lot of heavy lifting. Curious which specific earnings and valuation assumptions need to land for that $33.25 fair value to hold up.
Result: Fair Value of $33.25 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, ACADIA Pharmaceuticals still faces key risks, including reliance on NUPLAZID concentration and high stakes around upcoming remlifanserin trial data that could swing sentiment sharply.
Find out about the key risks to this ACADIA Pharmaceuticals narrative.
Next Steps
With mixed signals around ACADIA Pharmaceuticals so clear, it makes sense to move fast, check the underlying data yourself, and weigh both sides carefully before acting using the 4 key rewards and 1 important warning sign
Looking for more investment ideas beyond ACADIA Pharmaceuticals?
If you want a broader view beyond ACADIA Pharmaceuticals, use the Simply Wall Street Screener to quickly surface other stocks that fit clear, data backed criteria.
- Target dependable income opportunities by reviewing companies highlighted as potential 12 dividend fortresses that may suit investors who prioritize cash returns.
- Hunt for quality at a sensible price by checking the 50 high quality undervalued stocks that combine fundamentals with valuation checks.
- Prioritise capital protection first by focusing on the 74 resilient stocks with low risk scores that score well on balance sheet strength and volatility.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com